Impact of Clinical Pharmacist Intervention on diabetes-Related outcomes in a military treatment Facility;Impact de l'Intervention d'un Pharmacien Clinicien sur les Mesures de Résultats chez des Diabétiques Inscrits dans une Clinique de Santé pour Militaires

Annals of Pharmacotherapy

Volumn 46, Issue 3, 2012, Pages 353-357

  Wallgren, Stephanie ^a   Berry Cabán, Cristóbal S ^a   Bowers, Laura ^a  

^a WOMACK ARMY MEDICAL CENTER   (United States)

Author keywords

ADA treatment goals; Clinical pharmacist; Diabetes

Indexed keywords

HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; BLOOD PRESSURE REGULATION; CHOLESTEROL BLOOD LEVEL; CLINICAL PHARMACY; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; AGED, 80 AND OVER; BLOOD PRESSURE; CHOLESTEROL, LDL; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; MILITARY FACILITIES; PHARMACEUTICAL SERVICES; PHARMACISTS; PHYSICIANS, PRIMARY CARE; SOCIETIES, MEDICAL; TREATMENT OUTCOME; UNITED STATES;

EID: 84858030913     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q564     Document Type: Review

References (11)

1. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: Department of Health and Human Services, Centers for Disease Control and Prevention, 2011.
2. Knapp KK, Okamoto MP, Black BL. ASHP survey of ambulatory care pharmacy practice in health systems-2004. Am J Health Syst Pharm 2005;63:274-84.
3. Yanchick JK. Implementation of a drug therapy monitoring clinic in a primary-care setting. Am J Health Syst Pharm 2000;57:S30-4
4. Jameson JP, Baty PJ. Pharmacist collaborative management of poorly controlled diabetes mellitus: a randomized controlled trial. Am J Manag Care 2010;16:250-5.
5. Stading J, Herrmann J, Walters R, Destache C, Chock A. Impact of phar-macist intervention on diabetes patients in an ambulatory setting. Dia Spectr 2009;22:241-6.
6. Irons BK, Lenz RJ, Anderson SL, et al. A retrospective cohort analysis of the clinical effectiveness of a physician-pharmacist collaborative drug therapy management diabetes clinic. Pharmacotherapy 2002;22:1294-300.
7. Choe HM, Mitrovich S, Dubay D, et al. Proactive case management of high-risk patients with type 2 diabetes mellitus by a clinical pharmacist: a randomized controlled trial. Am J Manag Care 2005;11:253-60
8. American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care 2011;33:S11-S61.
9. UKPDS Group. Intensive blood-glucose control with sulfonylureas or in- sulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
10. UKPDS Group. Effect of intensive blood-glucose control with met- formin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.
11. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.